Roche: OAK Data Differentiates Tecentriq In Second-Line Lung Cancer
Executive Summary
ESMO data suggest that patients with no expression of PD-L1 who took Tecentriq were able to generate an immune response, a result Genentech believes reflects the particular mechanism of action compared to PD-1 inhibitors like Opdivo and Keytruda.
You may also be interested in...
PD-1 Deep Dive: Lung Cancer Market Braced For Change
Execs speculated during third-quarter earnings calls about the impact of FDA approval for Merck's Keytruda in first-line lung cancer and looked forward to readouts of combination studies, which could soon bring another market shake-up.
Keeping Track: Oncology Approvals And Responses To Complete Response Letters
The latest drug development news and highlights from our FDA Performance Tracker.
Roche Boasts Of Tecentriq's Broad Potential In 3Q Earnings Update
Roche CEO Severin Schwan called recently launched PD-L1 drug Tecentriq's CHF77m sales figure impressive when presenting the company's third-quarter earnings on Oct. 20. Roche also spotlighted its "comprehensive" immuno-oncology portfolio which is producing "quantity as well as quality" with five product launches in 12 months.